Elevance Health (NYSE:ELV) Announces Quarterly Earnings Results

Elevance Health (NYSE:ELV) released its earnings results on Wednesday. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84, Zacks reports. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the business posted $11.97 EPS. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health updated its FY 2026 guidance to 19.850- EPS.

Here are the key takeaways from Elevance Health’s conference call:

• Q1 adjusted diluted EPS of $12.58 beat expectations and management raised full‑year adjusted EPS guidance to at least $26.75, noting ~$1 per share of non‑recurring net investment income helped results.
• Management recorded a $935 million accrual tied to historical CMS risk‑adjustment data and is working with the agency toward resolution; they say it doesn’t change the outlook but it is a material contingent exposure.
• Company initiatives—leadership realignment, scaling AI (>$1 billion in digital/AI investments), and integrating Carelon/CareBridge—are cited as drivers of efficiency and demand, with reported benefits like ~20% lower readmissions and >10% savings on post‑acute care.
• Membership and segment cadence: total members rose to 45.4 million; Medicare performance is improving (targeting ≥2% operating margin for 2026), Medicaid faces planned high‑single‑digit membership declines and is seen as a 2026 trough, while ACA enrollment grew with a bronze‑plan mix causing seasonality.

Elevance Health Stock Down 0.1%

NYSE:ELV traded down $0.18 during mid-day trading on Friday, reaching $346.11. The stock had a trading volume of 148,650 shares, compared to its average volume of 1,858,392. The business’s 50 day moving average is $309.00 and its 200 day moving average is $331.66. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $427.54. The stock has a market cap of $76.03 billion, a P/E ratio of 14.73, a PEG ratio of 1.83 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.54.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. Elevance Health’s dividend payout ratio is currently 27.39%.

Institutional Investors Weigh In On Elevance Health

Large investors have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. bought a new stake in Elevance Health during the fourth quarter worth approximately $31,000. J.Safra Asset Management Corp bought a new stake in Elevance Health during the fourth quarter worth approximately $32,000. Jessup Wealth Management Inc bought a new stake in Elevance Health during the fourth quarter worth approximately $45,000. Garton & Associates Financial Advisors LLC bought a new stake in Elevance Health during the fourth quarter worth approximately $50,000. Finally, Rossby Financial LCC boosted its position in Elevance Health by 85.7% during the fourth quarter. Rossby Financial LCC now owns 156 shares of the company’s stock worth $55,000 after purchasing an additional 72 shares during the period. Institutional investors own 89.24% of the company’s stock.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results and guidance lift sentiment — ELV reported better-than-expected Q1 EPS and raised its 2026 adjusted EPS outlook (targets 12% EPS growth in 2027), signaling stronger profitability and upward earnings momentum. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Management cites medical-cost controls and AI-driven operating discipline as drivers of margin expansion and a higher annual profit forecast — supports sustainable margin improvement. Health insurer Elevance raises annual profit forecast
• Positive Sentiment: Investment income helped EPS — rising net investment income materially boosted Q1 results, offsetting some membership pressure. ELV Beats Q1 on rising net investment income
• Positive Sentiment: Analyst support: Evercore raised its price target to $360, adding buy-side validation for the beat-and-raise story. Evercore raises price target on Elevance
• Positive Sentiment: Shareholder return: Board declared a quarterly dividend (supports income-oriented investors and reduces downside risk).
• Neutral Sentiment: Analyst stance mixed — Robert W. Baird raised its target to $331 but moved to a “neutral” rating, reflecting more cautious near-term expectations despite higher valuation work. Baird updates target and rating
• Neutral Sentiment: Operational caveat: Management noted membership declines; the topline impact is being offset by investment income and cost controls — watch membership trends for sustainability. Valuation and mixed Q1 draw attention
• Negative Sentiment: Legal risk: A law firm (Kirby McInerney LLP) has launched an investor investigation into potential securities-law claims involving Elevance and senior management — introduces regulatory/legal overhang and potential litigation risk. Investor alert: Kirby McInerney investigates Elevance

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jefferies Financial Group lowered their target price on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday. Sanford C. Bernstein lifted their target price on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft lifted their target price on Elevance Health from $332.00 to $363.00 and gave the company a “hold” rating in a research note on Thursday. The Goldman Sachs Group boosted their price target on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Weiss Ratings downgraded Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Eleven research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $384.65.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.